Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma (Q51773858)

12 April 2018

title

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma (English)

1 reference

12 April 2018

1 reference

Steven M Grunberg

1 reference

12 April 2018

Martin H Weiss

1 reference

12 April 2018

Christy A Russell

1 reference

12 April 2018

Irving M Spitz

1 reference

12 April 2018

Jamshid Ahmadi

1 reference

12 April 2018

Alfredo Sadun

1 reference

12 April 2018

Regine Sitruk-Ware

1 reference

12 April 2018

publication date

1 December 2006

1 reference

12 April 2018

published in

Cancer Investigation

1 reference

12 April 2018

volume

1 reference

12 April 2018

issue

1 reference

12 April 2018

page(s)

727-733

1 reference

12 April 2018

Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Early pregnancy termination with mifepristone and misoprostol in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

The use of progesterone antagonists and progesterone receptor modulators in contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Role of antiprogestational therapy for meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

The Endocrine Effects of Long-Term Treatment with Mifepristone (RU 486)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Treatment of depression with antiglucocorticoid drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Rapid reversal of psychotic depression using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist. An expected or unexpected effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Mifepristone: clinical application in general gynecology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Surveillance for endometrial cancer in women receiving tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

Meningiomas in lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601062339

10.1080/07357900601062339

21 January 2018

Identifiers

DOI

1 reference

12 April 2018

1 reference

12 April 2018